HIV PrEP Trials: The Road to Success

Area of Science:

• Infectious Diseases
• Public Health
• Pharmacology

Background:

• The global Human Immunodeficiency Virus (HIV) epidemic persists, with current strategies insufficient for control.
• Antiretroviral pre-exposure prophylaxis (PrEP) offers a potential biomedical intervention to reduce HIV transmission.
• Topical or oral PrEP has shown promise in recent clinical trials, but results are not universally positive.

Purpose of the Study:

• To evaluate the efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.
• To identify factors influencing PrEP effectiveness, including administration routes and adherence levels.
• To address the need for further research to define optimal conditions for PrEP implementation.

Main Methods:

• Review of recent clinical trials investigating topical and oral antiretroviral pre-exposure prophylaxis (PrEP).
• Analysis of factors impacting PrEP efficacy, including adherence and drug exposure.
• Consideration of potential challenges such as drug resistance and monitoring adherence.

Main Results:

• Four clinical trials demonstrated positive outcomes for antiretroviral PrEP administration.
• Two trials failed to show a significant benefit, highlighting the need for further investigation.
• Adherence is strongly linked to protection, but the precise required level remains undetermined.
• Low rates of drug resistance were observed in trials, but it remains a concern for individuals who seroconvert on PrEP.

Conclusions:

• Antiretroviral pre-exposure prophylaxis (PrEP) is a promising HIV prevention tool, but its effectiveness is context-dependent.
• Further research is crucial to establish optimal populations, conditions, and adherence levels for effective PrEP implementation.
• Objective adherence monitoring and drug exposure testing are necessary for future PrEP studies.
• The potential for drug resistance necessitates careful monitoring in individuals using PrEP.